BRIEF: Joinn Lab swings to red on lower revenue, falling gross margin

6127.HK
603127.SHG

Joinn Laboratories (China) Co. Ltd. (6127.HK; 603127.SH), China’s leading non-clinical contract research organization (CRO), said on Wednesday its revenue fell 15.5% to 486 million yuan ($68.3 million) in the third quarter, while its net profit tumbled 58% to 99.44 million yuan.

The company reported a net loss of 70.31 million yuan for the first three quarters of the year, reversing a profit of 328 million yuan in the same period of last year, mainly due to intensified competition in the industry, falling sales and a declining gross margin, as well as a drop in the fair value of its biological assets.

Joinn’s Hong Kong-listed shares rose 1.7% to HK$8.99 in early Thursday trade.

By A. Au

To subscribe to Bamboo Works free weekly newsletter, click here

,
,

Related Articles

RELATED ARTICLES

No related posts.

Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

So-Young provides cosmetic services

So-Young finds beauty in growing economies of scale

The company’s revenue rose 33% in the second quarter, as aesthetic treatment services from its growing chain of self-operated clinics jumped 130% Key Takeaways: So-Young’s revenue rose 33% in the…
SY.US
WuXi XDC delivered strong half-year earnings

Bulging order book for bioconjugates lifts WuXi XDC profits

The provider of outsourced pharmaceutical services has delivered unexpectedly strong half-year earnings and has launched its first overseas production hub Key Takeaways: WuXi XDC began operations in August at a…
2268.HK